FCMI
AIMT

Foresite Capital Management II’s Aimmune Therapeutics AIMT Stock Holding History

Foresite Capital Management II’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-437,900
Closed -$13.9M – 12
2018
Q1 		$13.9M Buy
+437,900
New +$15.4M 4.62% 6

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Foresite Capital Management II's AIMT Position: Q4 2019 in Review

Foresite Capital Management II sold out of Aimmune Therapeutics (AIMT) in Q4 2019, closing a stake of 2,605,499 shares — an estimated $54.6M sold.

Foresite Capital Management II first reported a position in AIMT in Q3 2015 and held it in 17 quarters. The position peaked at $117M in Q4 2017. 155 funds tracked by Wall St. Rank hold AIMT as of Q4 2019.

  • Foresite Capital Management II reported no remaining Aimmune Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Foresite Capital Management II sold 2,605,499 Aimmune Therapeutics shares in Q4 2019, an estimated $54.6M.
  • Foresite Capital Management II first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 17 quarters.
  • Foresite Capital Management II's Aimmune Therapeutics position peaked at $117M in Q4 2017.
  • 155 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2019.

Based on Foresite Capital Management II's 13F filing for Q4 2019, filed 5 Feb 2020.